Stock Market News
Instem wins contract with Fortune 500 player
Life science IT solutions provider Instem boasted on Wednesday that a large Fortune 500 pharmaceuticals company has adopted its Samarind RMS software-as-a-service (SaaS) solution in a contract worth approximately $0.75m.
The AIM-quoted company said that approximately 80% of the contract value will be recognised in 2018, followed by annual recurring revenue of $169,000.
Phil Reason, chief executive of Instem plc, said the client company ranks among the top 25 on the Fortune 500, which would suggest it was either CVS Health, McKesson, AmerisourceBergen or Cardinal Health.
Reason said the contract win "continues the good momentum experienced with our regulatory information management solutions 2017 to date and particularly Instem's success in the medical device field" and added his pleasure that the contract was as for SaaS with the recurring revenues that implies.
Samarind RMS software provides companies with management capabilities for product information, facilitating initial marketing authorisation and supporting ongoing regulatory compliance. Businesses can use the software to track their registered products worldwide through the maintenance of an integrated database, thus providing firms with a single place to find, analyse and act on a wealth of product and regulatory information.
As of 0905 BST, Instem plc's shares were up 2.63% at 302.00p.
The AIM-quoted company said that approximately 80% of the contract value will be recognised in 2018, followed by annual recurring revenue of $169,000.
Phil Reason, chief executive of Instem plc, said the client company ranks among the top 25 on the Fortune 500, which would suggest it was either CVS Health, McKesson, AmerisourceBergen or Cardinal Health.
Reason said the contract win "continues the good momentum experienced with our regulatory information management solutions 2017 to date and particularly Instem's success in the medical device field" and added his pleasure that the contract was as for SaaS with the recurring revenues that implies.
Samarind RMS software provides companies with management capabilities for product information, facilitating initial marketing authorisation and supporting ongoing regulatory compliance. Businesses can use the software to track their registered products worldwide through the maintenance of an integrated database, thus providing firms with a single place to find, analyse and act on a wealth of product and regulatory information.
As of 0905 BST, Instem plc's shares were up 2.63% at 302.00p.
Related share prices |
---|
Instem (INS) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price